Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

GoodRx Announces Date for Second Quarter 2022 Earnings Release and Conference Call

GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it will release its second quarter 2022 financial results after U.S. markets close on Monday, August 8, 2022. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company’s business outlook. Prior to the call, GoodRx will issue a press release containing a link to a shareholder letter and the Company’s second quarter 2022 financial results on its investor relations website at https://investors.goodrx.com.

A live webcast of the event will be available on the investor relations website at https://investors.goodrx.com.

To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

About GoodRx

GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $40 billion and are one of the most downloaded medical apps over the past decade.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.